-

09:53:07 AM

SOPH Stock News

SOPH - SOPHiA Genetics SA

08/09/22 7:05 AM

Nasdaq : SOPH

earnings

SOPHiA GENETICS Reports Financial Results for the Second Quarter of Fiscal 2022

SOPHiA GENETICS SA (Nasdaq: SOPH), a cloud-native software company in the healthcare space, today reported financial results for the second quarter ended June 30,

RHEA-AI

neutral

08/04/22 10:16 AM

Nasdaq : SOPH

conferences

SOPHiA GENETICS to Host Investor Day on September 20, 2022, in New York City

SOPHiA GENETICS SA (Nasdaq: SOPH), a cloud-native software company in the healthcare space, announced today it will host its first-ever Investor Day on Tuesday, September 20, 2022, at PUBLIC Hotel in New York City. The event will

RHEA-AI

neutral

07/29/22 7:00 AM

Nasdaq : SOPH

conferences

SOPHiA GENETICS to Participate in Canaccord Genuity 42nd Annual Growth Conference

SOPHiA GENETICS SA (Nasdaq: SOPH), a leader in data-driven medicine, announced today Chief Financial Officer, Ross Muken, will attend and be a panelist at the Canaccord Genuity 42 nd Annual Growth Conference on Thursday, August

RHEA-AI

neutral

07/14/22 7:00 AM

Nasdaq : SOPH

earnings

SOPHiA GENETICS to Announce Financial Results for the Second Quarter of Fiscal 2022 on August 9, 2022

SOPHiA GENETICS SA (Nasdaq: SOPH), a leader in data-driven medicine, today announced it will release its financial results for the second quarter of fiscal 2022 before U.S. markets open on Tuesday, August 9, 2022. SOPHiA GENETICS

RHEA-AI

neutral

06/15/22 11:15 AM

Nasdaq : SOPH

SOPHiA GENETICS Publishes Results of 2022 Annual General Meeting

SOPHiA GENETICS SA (Nasdaq: SOPH) (" the Company"), is pleased to announce the Annual General Meeting (" the Meeting") was held at the Company's headquarters, rue du Centre 172, 1025 St-Sulpice, VD, Switzerland, earlier today at 2:00

RHEA-AI

neutral

06/15/22 9:55 AM

Nasdaq : SOPH

SOPHiA GENETICS Publishes Environmental, Social and Governance Impact Summary

SOPHiA GENETICS SA (Nasdaq: SOPH) ("the Company"), today announced that the Company has published its first Environmental, Social and Governance Impact Summary ("ESG Impact Summary"). The ESG Impact Summary highlights the Company's

RHEA-AI

neutral

06/09/22 8:00 AM

Nasdaq : SOPH

SOPHiA GENETICS Launches New Solution to Advance Chronic Lymphocytic Leukemia Care, in Collaboration with IDIBAPS

SOPHiA GENETICS (Nasdaq: SOPH), the Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) of Barcelona, and the Spanish Diagnóstica Longwood today announced from the European Hematology Association Congress in Vienna that

RHEA-AI

very positive

06/06/22 11:12 AM

Nasdaq : SOPH

clinical trial

SOPHiA GENETICS Provides an Update on its DEEP-Lung-IV Multimodal Clinical Study at ASCO 2022

Study leverages deep learning-enabled analysis of the aggregation of real-world multimodal data to validate predictive signatures associated with response to immunotherapy and prognosis of patients with stage IV non-small cell lung cancerNearly 20 participating sites activated worldwide with over

RHEA-AI

positive

05/10/22 7:00 AM

Nasdaq : SOPH

earnings

SOPHiA GENETICS Reports Financial Results for the First Quarter of Fiscal 2022

SOPHiA GENETICS SA (Nasdaq: SOPH), a leader in data-driven medicine, today reported financial results for the first quarter ended

RHEA-AI

neutral

05/05/22 8:27 AM

Nasdaq : SOPH

management

SOPHiA GENETICS Announces Nomination of Jean-Michel Cosséry to Board of Directors

SOPHiA GENETICS (Nasdaq: SOPH), a leader in data-driven medicine, today announced the nomination of Jean-Michel Cosséry to its Board of Directors. The Board of Directors will propose the appointment of Mr. Cosséry as a member of the

RHEA-AI

very positive